Hansoh Pharma (03692.HK) Shares Surge Over 4% Post Earnings as Net Profit Soars Over 30% YoY on Strong Aumolertinib Sales

According to the Zhitong Finance app, Hansoh Pharma (03692) rose over 4% after its earnings report. As of press time, it increased by 4.48%, trading at HK$21 with a turnover of HK$73.9313 million.

On the news front, on March 21, Hansoh Pharma announced its annual performance for the year ended December 31, 2024. The group achieved revenue of RMB 12.261 billion (same unit hereinafter), representing a year-on-year increase of 21.35%; profit attributable to owners of the parent company amounted to RMB 4.372 billion, marking a year-on-year increase of 33.39%; basic earnings per share were RMB 0.74, and a final dividend of HKD 0.1353 per share is proposed. For the year ended December 31, 2024, revenue from innovative drugs and collaboration products reached approximately RMB 9.477 billion, accounting for about 77.3% of total revenue, becoming the core driver for sustainable growth in the company’s performance.

CICC issued a research report stating that the company's performance exceeded the bank's expectations, mainly due to the upfront payment from product licensing and the rapid sales growth of Almonertinib. The company's core product, Almonertinib, used for maintenance treatment in patients with Stage III unresectable NSCLC after concurrent radiotherapy, was approved for marketing in March 2025. Two other indications for this product (adjuvant treatment for NSCLC and first-line treatment in combination with chemotherapy for NSCLC) are still in the NDA stage. The bank expects them to be potentially approved for marketing in 1H25 and 2H25, respectively. It is recommended to pay attention to the progress of indication expansion and national reimbursement negotiations.